Category: Cardiac Implants
New data presented last week at the annual Transcatheter Cardiovascular Therapies meeting showed Boston Scienfitic's Watchman anti-stoke device to be comparable to treatment with the anti-coagulant warfarin.
CE Mark approval expands the company's portfolio of cardiac rhythm devices with MRI compatibility.
St. Jude Medical lands European approval to market its Tendril STS and IsoFlex Optim leads as safe for MRI scanning, adding that the company's just getting started on a larger MRI-safe campaign.
St. Jude Medical says that its Quartet quadripolar leads "performed better than bipolar leads of any kind" in a recent mega-study.
Medical device giant St. Jude Medical (NYSE:STJ) had high praise for its own quadripolar leads, saying that blow away any competition from older bipolar leads.
Another team of researchers is working on pacemakers that use motion for power, with aims to eliminate reliance on depletable batteries.
Swiss researchers are taking a page from their country's most iconic products to change how pacemakers are powered inside the body.
Medtech titan Medtronic enrolls the 1st patients in the AdaptResponse clinical trial to evaluate its adaptive cardiac rhythm management technology.
Medtronic (NYSE:MDT) touted the launch of its AdaptResponse trial, the largest study of its kind evaluating the company's AdaptivCRT algorithm for personalizing cardiac resynchronization therapy in treatment of heart failure.
An FDA advisory panel is slated to convene yet again in October to consider the safety and efficacy of Boston Scientific's Watchman anti-stroke heart repair device.